Is there any place for the chimeric antibody against tumor necrosis factor (infliximab) in the treatment of patients with active ulcerative colitis? (EN)

Maria Mylonaki, J.K. Triantafillidis,

SUMMARY We attempt to summarize the current aspects concerning the role of the chimeric antibody against tumor necrosis factor-alpha (Infliximab – Remicade) in patients with active ulcerative colitis. Experimental and clinical data suggest that, apart from Crohn’s disease, tumor necrosis factor also plays quite an important role in the pathogenesis of ulcerative colitis as well. So far, there are limited data on the use of infliximab in animal models of ulcerative colitis and in patients with ulcerative and indeterminate colitis and pouchitis. Although the existing clinical, endoscopic and laboratory evidence for the efficacy of infliximab in the treatment of ulcerative colitis are controversial, we can support the assumption that a proportion of patients may benefit from this treatment. In addition, treatment with infliximab appeared to be well-tolerated at the doses studied. Further, ongoing, controlled studies are investigating the potential efficacy and safety of infliximab in patients with active ulcerative colitis. Key words: Infliximab, Remicade, Ulcerative colitis, Inflammatory bowel disease Department of Gastroenterology Saint Panteleimon General Hospital Nicea, Greece Author for correspondence: John K. Triantafillidis, 8, Kerasountos street, 12461, Haidari, Athens, Greece, Tel: Greece-210-5819481, Fax: Greece-210-5810970, e-mail: jkt@panafonet.gr (EN)

info:eu-repo/semantics/article

info:eu-repo/semantics/publishedVersion

Ελληνική Γαστροεντερολογική Εταιρία

Annals of Gastroenterology

Current views

Αγγλική γλώσσα

2007-03-19

http://www.annalsgastro.gr/index.php/annalsgastro/article/view/284

Hellenic Society of Gastroenterology (EN)

1792-7463

1108-7471

Annals of Gastroenterology; Volume 17, No 2 (2004) (EN)